{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:35:41Z","timestamp":1793885741720,"version":"4.8.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtct.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:26:30Z","timestamp":1783495590000},"page":"1372-1388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Conventional Chimeric Antigen Receptors: Expanding the Targetable Antigen Landscape in Chimeric Antigen Receptor-T Cell Therapy"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5660-8959","authenticated-orcid":false,"given":"Umida","family":"Yoziyeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6159-7566","authenticated-orcid":false,"given":"Alexey","family":"Yumashev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-8397","authenticated-orcid":false,"given":"Shakhodat","family":"Kobilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0447-0256","authenticated-orcid":false,"given":"Dildora","family":"Khaydarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dildor","family":"Numonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0124-9989","authenticated-orcid":false,"given":"Nilufar","family":"Akhmedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matlyuba","family":"Saidkarimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8827-2008","authenticated-orcid":false,"given":"Zebo","family":"Khudoykulova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0001","doi-asserted-by":"crossref","DOI":"10.1111\/tan.70550","article-title":"Chimeric antigen receptor T-cell therapy: more than an anti-cancer drug","volume":"107","author":"Schenk","year":"2026","journal-title":"HLA"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s41232-025-00398-x","article-title":"Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors","volume":"45","author":"Khodabandehloo","year":"2025","journal-title":"Inflamm Regen"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0003","article-title":"CAR-T cell therapy based on a TCR mimic nanobody targeting an intracellular antigen for solid cancers","volume":"33","author":"Lin","year":"2025","journal-title":"Mol Ther Oncol"},{"issue":"7988","key":"10.1016\/j.jtct.2026.07.003_bib0004","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41586-023-06706-0","article-title":"Targeting of intracellular oncoproteins with peptide-centric CARs","volume":"623","author":"Yarmarkovich","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0005","doi-asserted-by":"crossref","first-page":"9751","DOI":"10.1038\/s41467-024-54150-z","article-title":"Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2026.07.003_bib0006","article-title":"Ligand-based CAR-T cell: different strategies to drive T cells in future new treatments","volume":"13","author":"Ram\u00edrez-Chac\u00f3n","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jtct.2026.07.003_bib0007","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.3390\/ijms25115634","article-title":"Anti-idiotypic VHHs and VHH-CAR-T cells to tackle multiple myeloma: different applications call for different antigen-binding moieties","volume":"25","author":"Hanssens","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66102-2","article-title":"Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer","volume":"16","author":"Park","year":"2025","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.003_bib0009","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41417-021-00307-7","article-title":"TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential","volume":"28","author":"Poorebrahim","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"22","key":"10.1016\/j.jtct.2026.07.003_bib0010","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.3390\/cancers16223776","article-title":"Unlocking intracellular oncology targets: the unique role of antibody-based T-cell receptor mimic (TCRm) therapeutics in T-cell engagers (TCEs) and antibody-drug conjugates (ADCs)","volume":"16","author":"Molldrem","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.jtct.2026.07.003_bib0011","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/sj.gt.3301570","article-title":"A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes","volume":"8","author":"Willemsen","year":"2001","journal-title":"Gene Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.003_bib0012","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/gt.2014.30","article-title":"Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H","volume":"21","author":"Inaguma","year":"2014","journal-title":"Gene Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.07.003_bib0013","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/leu.2016.373","article-title":"Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen","volume":"31","author":"Rafiq","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.07.003_bib0014","doi-asserted-by":"crossref","first-page":"S447","DOI":"10.1016\/S2152-2650(21)01994-7","article-title":"CT-080: a tumor-agnostic TCR-mimic CAR-T cell specific for NDC80 targets multiple hematological malignancies","volume":"21","author":"Klatt","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.003_bib0015","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00109-025-02585-2","article-title":"Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager","volume":"103","author":"Ebrahimi","year":"2025","journal-title":"J Mol Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.003_bib0016","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2022008304","article-title":"Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia","volume":"7","author":"Kirkey","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004035","article-title":"Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1\/HLA-A2 for cancer immunotherapy","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0018","article-title":"Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma","volume":"12","author":"Liu","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtct.2026.07.003_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1027548","article-title":"TCR mimic compounds for pHLA targeting with high potency modalities in oncology","volume":"12","author":"Gerber","year":"2022","journal-title":"Front Oncol"},{"issue":"791","key":"10.1016\/j.jtct.2026.07.003_bib0020","doi-asserted-by":"crossref","first-page":"eado9371","DOI":"10.1126\/scitranslmed.ado9371","article-title":"CAR T cells based on fully human T cell receptor\u2013mimetic antibodies exhibit potent antitumor activity in vivo","volume":"17","author":"Salzler","year":"2025","journal-title":"Sci Transl Med"},{"issue":"18","key":"10.1016\/j.jtct.2026.07.003_bib0021","article-title":"Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice","volume":"133","author":"Spanier","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2026.07.003_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1207108","article-title":"Regulatory T cells targeting a pathogenic MHC class II: insulin peptide epitope postpone spontaneous autoimmune diabetes","volume":"14","author":"Obarorakpor","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0023","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/2159-8290.CD-RW2021-162","article-title":"Peptide-centric CAR-T cells target unmutated intracellular oncoproteins","volume":"12","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0024","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ccell.2021.12.011","article-title":"A roadmap for driving CAR T cells toward the oncogenic immunopeptidome","volume":"40","author":"Irving","year":"2022","journal-title":"Cancer Cell"},{"issue":"67","key":"10.1016\/j.jtct.2026.07.003_bib0025","doi-asserted-by":"crossref","first-page":"eabn9189","DOI":"10.1126\/sciimmunol.abn9189","article-title":"CAR keys to unlock the intracellular immunopeptidome","volume":"7","author":"Griffin","year":"2022","journal-title":"Sci Immunol"},{"issue":"90","key":"10.1016\/j.jtct.2026.07.003_bib0026","doi-asserted-by":"crossref","first-page":"eadj5792","DOI":"10.1126\/sciimmunol.adj5792","article-title":"Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion","volume":"8","author":"Sun","year":"2023","journal-title":"Sci Immunol"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.003_bib0027","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ccell.2025.05.006","article-title":"Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy","volume":"43","author":"Benton","year":"2025","journal-title":"Cancer Cell"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.07.003_bib0028","article-title":"O15.05 development of peptide-centric CARs targeting IGFBPL-1 for cancer immunotherapy in small-cell lung cancer","volume":"14","author":"McEnroe","year":"2026","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.003_bib0029","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41551-025-01563-w","article-title":"Generation of T cells with reduced off-target cross-reactivities by engineering co-signalling receptors","volume":"10","author":"Cabezas-Caballero","year":"2026","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jtct.2026.07.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2023.102329","article-title":"Tumor immune evasion through loss of MHC class-I antigen presentation","volume":"83","author":"Sari","year":"2023","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0031","first-page":"22","article-title":"T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins","volume":"2","author":"Xu","year":"2019","journal-title":"Antib Ther"},{"key":"10.1016\/j.jtct.2026.07.003_bib0032","series-title":"United States Patent Application US 2025\/0066760 A1","article-title":"Chimeric antigen receptor (CAR) vectors and libraries and methods of high throughput CAR screening","author":"Maris","year":"2025"},{"issue":"8","key":"10.1016\/j.jtct.2026.07.003_bib0033","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0034","first-page":"28","article-title":"Interferon gamma, MHC class I regulation and immunotherapy","volume":"3","author":"G\u00f3mez-Herranz","year":"2022","journal-title":"J Cell Signal"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.003_bib0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nchembio.2565","article-title":"Rewiring T-cell responses to soluble factors with chimeric antigen receptors","volume":"14","author":"Chang","year":"2018","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jtct.2026.07.003_bib0036","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3389\/fimmu.2018.02040","article-title":"NKG2D ligands-critical targets for cancer immune escape and therapy","volume":"9","author":"Schmiedel","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.07.003_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00441","article-title":"NKG2D: a master regulator of immune cell responsiveness","volume":"9","author":"Wensveen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.07.003_bib0038","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fimmu.2014.00106","article-title":"Molecular bases for the regulation of NKG2D ligands in cancer","volume":"5","author":"Huergo-Zapico","year":"2014","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jtct.2026.07.003_bib0039","first-page":"945","article-title":"Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo","volume":"9","author":"Deng","year":"2019","journal-title":"Am J Cancer Res"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.003_bib0040","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0041","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s40425-019-0642-9","article-title":"T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells","volume":"7","author":"Yang","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0042","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","article-title":"Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells","volume":"11","author":"Han","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2026.07.003_bib0043","article-title":"shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.07.003_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1002361","article-title":"Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.07.003_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115740","article-title":"Co-expression of IL-4\/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment","volume":"168","author":"Zhou","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jtct.2026.07.003_bib0046","article-title":"Co-expression of IL-15\/IL-15Ra complex enhances NKG2D-CAR T cell-mediated anti-pancreatic cancer immunity by activating the JAK\/STAT5 signaling pathway","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.07.003_bib0047","article-title":"Sodium valproate enhances efficacy of NKG2D CAR-T cells against glioblastoma","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.003_bib0048","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1111\/cas.15828","article-title":"Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer","volume":"114","author":"Zhang","year":"2023","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0049","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.07.003_bib0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-141009","article-title":"Ligand based CAR T-cell targeting BAFF receptors Asa novel therapy for B cell malignancies","volume":"136","author":"Parameswaran","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.003_bib0051","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jtct.2026.07.003_bib0052","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.003_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077769","article-title":"Glioma IL13R\u03b12 is associated with mesenchymal signature gene expression and poor patient prognosis","volume":"8","author":"Brown","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jtct.2026.07.003_bib0055","first-page":"4702","article-title":"IL13RA2 is overexpressed in malignant gliomas and related to clinical outcome of patients","volume":"12","author":"Zeng","year":"2020","journal-title":"Am J Transl Res"},{"issue":"33","key":"10.1016\/j.jtct.2026.07.003_bib0056","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112006119","article-title":"Engineered IL13 variants direct specificity of IL13R\u03b12-targeted CAR T cell therapy","volume":"119","author":"Stern","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.003_bib0057","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.07.003_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00380","article-title":"Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks","volume":"9","author":"Peixoto","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0059","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41698-025-01016-2","article-title":"Mucin-1: a promising pan-cancer therapeutic target","volume":"9","author":"Grewal","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jtct.2026.07.003_bib0060","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.003_bib0061","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10040732","article-title":"Gb3\/cd77 is a predictive marker and promising therapeutic target for head and neck cancer","volume":"10","author":"Garc\u00eda-Hevia","year":"2022","journal-title":"Biomedicines"},{"issue":"571","key":"10.1016\/j.jtct.2026.07.003_bib0062","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci Transl Med"},{"issue":"7903","key":"10.1016\/j.jtct.2026.07.003_bib0063","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0064","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9010059","article-title":"Application of CAR-T cell therapy beyond oncology: autoimmune diseases and viral infections","volume":"9","author":"Zmievskaya","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jtct.2026.07.003_bib0065","series-title":"The EBMT\/EHA CAR-T Cell Handbook","first-page":"147","article-title":"Management of hypogammaglobulinaemia and B-cell aplasia","author":"Topp","year":"2022"},{"key":"10.1016\/j.jtct.2026.07.003_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1686107","article-title":"The past, present, and future of anti-idiotype antibodies","volume":"16","author":"Murphy","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0067","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2341443","article-title":"Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions","volume":"16","author":"Mullin","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.jtct.2026.07.003_bib0068","article-title":"Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells","author":"Liu","year":"2025","journal-title":"bioRxiv [Preprint]"},{"issue":"835","key":"10.1016\/j.jtct.2026.07.003_bib0069","doi-asserted-by":"crossref","first-page":"eadr9382","DOI":"10.1126\/scitranslmed.adr9382","article-title":"Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells","volume":"18","author":"Cohen","year":"2026","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.003_bib0070","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.003_bib0071","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.2019001859","article-title":"A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells","volume":"135","author":"Ruella","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.07.003_bib0072","article-title":"Comparison of reverse transcription quantitative real-time PCR, flow cytometry, and immunohistochemistry for detection of monoclonality in lymphomas","volume":"2014","author":"St\u00e5hlberg","year":"2014","journal-title":"ISRN Oncol"},{"issue":"21","key":"10.1016\/j.jtct.2026.07.003_bib0073","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1158\/1078-0432.CCR-20-2754","article-title":"CAR T cells targeting human immunoglobulin light chains eradicate mature B-cell malignancies while sparing a subset of normal B cells","volume":"27","author":"Ranganathan","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jtct.2026.07.003_bib0074","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2006-04-017061","article-title":"T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells","volume":"108","author":"Vera","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.003_bib0075","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.jtct.2026.07.003_bib0076","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/10428190600612909","article-title":"Molecular analysis of light-chain switch and acute lymphoblastic leukemia transformation in two follicular lymphomas: implications for lymphomagenesis","volume":"47","author":"Kobrin","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.003_bib0077","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cyto.b.22107","article-title":"The patterns and diagnostic significance of the lack of surface immunoglobulin light chain on mature B cells in clinical samples for lymphoma workup","volume":"104","author":"Huang","year":"2023","journal-title":"Cytom B: Clin Cytom"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0078","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.07.003_bib0079","article-title":"CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"issue":"6295","key":"10.1016\/j.jtct.2026.07.003_bib0080","first-page":"179","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science (1979)"},{"key":"10.1016\/j.jtct.2026.07.003_bib0081","doi-asserted-by":"crossref","first-page":"255","DOI":"10.18609\/cgti.2018.026","article-title":"Advances in targeting CAR-T therapy for immune-mediated diseases","volume":"4","author":"Lee","year":"2018","journal-title":"Cell Gene Ther Insights"},{"issue":"23","key":"10.1016\/j.jtct.2026.07.003_bib0082","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"issue":"107","key":"10.1016\/j.jtct.2026.07.003_bib0083","doi-asserted-by":"crossref","first-page":"eadm8186","DOI":"10.1126\/sciimmunol.adm8186","article-title":"Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-\u03b3","volume":"10","author":"Peng","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jtct.2026.07.003_bib0084","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1562662","article-title":"Chimeric autoantibody receptor T cells specifically eliminate Graves\u2019 Disease autoreactive B cells","volume":"16","author":"Cheever","year":"2025","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jtct.2026.07.003_bib0085","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4049\/jimmunol.1701800","article-title":"Targeting antigen-specific B cells using antigen-expressing transduced regulatory T cells","volume":"201","author":"Zhang","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2026.07.003_bib0086","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1601385","article-title":"Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipients","volume":"16","author":"Valent\u00edn-Quiroga","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.003_bib0087","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/tan.15156","article-title":"Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation","volume":"102","author":"Betriu","year":"2023","journal-title":"HLA"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.003_bib0088","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/tan.15146","article-title":"Chimeric HLA antibody receptor T cells to target HLA-specific B cells in solid organ transplantation","volume":"102","author":"Gille","year":"2023","journal-title":"HLA"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.07.003_bib0089","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1182\/blood-2025-4128","article-title":"Elimination of alloantibody responses using chimeric HLA-II antibody receptor T cells","volume":"146","author":"Papadaki","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.003_bib0090","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ymthe.2025.01.009","article-title":"Depletion of alloreactive B cells by drug-resistant chimeric alloantigen receptor T cells to prevent transplant rejection","volume":"33","author":"Dragon","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2026.07.003_bib0091","article-title":"Ligand-based CAR-T cell: different strategies to drive T cells in future new treatments","volume":"13","author":"Ram\u00edrez-Chac\u00f3n","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0092","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/ndt\/gfae160","article-title":"Chimeric HLA antibody receptor T cell therapy for humoral transplant rejection","volume":"40","author":"Arana","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jtct.2026.07.003_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115888","article-title":"The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: an overview of clinical trials","volume":"169","author":"Moradi","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jtct.2026.07.003_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114358","article-title":"Advances in modular control of CAR-T therapy with adapter-mediated CARs","volume":"187","author":"McCue","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jtct.2026.07.003_bib0095","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1491282","article-title":"Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects","volume":"12","author":"Alidadi","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jtct.2026.07.003_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114583","article-title":"A general logic-gating framework for CAR-T and nanocarrier cancer therapies: a cross-platform comparative analysis of logic architectures and their molecular implementation strategies","volume":"391","author":"Rehorst","year":"2026","journal-title":"J Controlled Release"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0097","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s42003-023-04978-w","article-title":"Activation-inducible CAR expression enables precise control over engineered CAR T cell function","volume":"6","author":"Fraessle","year":"2023","journal-title":"Commun Biol"},{"issue":"6625","key":"10.1016\/j.jtct.2026.07.003_bib0098","first-page":"eaba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science (1979)"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.003_bib0099","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221988","article-title":"Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy","volume":"221","author":"Lin","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtct.2026.07.003_bib0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1388475","article-title":"Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review","volume":"14","author":"Moradi","year":"2024","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.003_bib0101","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1007\/s12094-025-04185-5","article-title":"Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology","volume":"28","author":"Dong","year":"2026","journal-title":"Clin Transl Oncol"},{"issue":"13","key":"10.1016\/j.jtct.2026.07.003_bib0102","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1016\/j.cell.2026.06.002","article-title":"AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy","volume":"189","author":"Baker","year":"2026","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.003_bib0103","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41467-025-68272-5","article-title":"AI-guided CAR designs and targeted pathway modulation to enhance multi-antigen CAR T cell durability and overcome antigen escape","volume":"17","author":"Ansari","year":"2026","journal-title":"Nat Commun"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600535X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600535X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:20:50Z","timestamp":1793884850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672600535X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":103,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S266663672600535X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.003","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond Conventional Chimeric Antigen Receptors: Expanding the Targetable Antigen Landscape in Chimeric Antigen Receptor-T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}